FCMT
FLNA

Founders Capital Management (Texas)’s Filana Therapeutics FLNA Stock Holding History

Founders Capital Management (Texas)’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70
Closed -$2.06K – 388
2024
Q3 		$2.06K Hold
70
– – ﹤0.01% 330
2024
Q2 		$865 Hold
70
– – ﹤0.01% 349
2024
Q1 		$1.42K Hold
70
– – ﹤0.01% 333
2023
Q4 		$1.58K Hold
70
– – ﹤0.01% 357
2023
Q3 		$1.17K Hold
70
– – ﹤0.01% 380
2023
Q2 		$1.72K Hold
70
– – ﹤0.01% 364
2023
Q1 		$2K Hold
70
– – ﹤0.01% 365
2022
Q4 		$2K Hold
70
– – ﹤0.01% 359
2022
Q3 		$3K Hold
70
– – ﹤0.01% 361
2022
Q2 		$2K Sell
70
-35
-33% -$884 ﹤0.01% 382
2022
Q1 		$5K Hold
105
– – ﹤0.01% 289
2021
Q4 		$5K Hold
105
– – ﹤0.01% 289
2021
Q3 		$7K Buy
+105
New +$8.76K ﹤0.01% 284

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Founders Capital Management (Texas)'s FLNA Position: Q4 2024 in Review

Founders Capital Management (Texas) sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 70 shares — an estimated $2.06K sold.

Founders Capital Management (Texas) first reported a position in FLNA in Q3 2021 and held it in 13 quarters. The position peaked at $7K in Q3 2021. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • Founders Capital Management (Texas) reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 70 Filana Therapeutics shares in Q4 2024, an estimated $2.06K.
  • Founders Capital Management (Texas) first reported a position in Filana Therapeutics in Q3 2021 and held it in 13 quarters.
  • Founders Capital Management (Texas)'s Filana Therapeutics position peaked at $7K in Q3 2021.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Founders Capital Management (Texas)'s 13F filing for Q4 2024, filed 13 Jan 2025.